The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of the addition of metformin to abiraterone
on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). The
half the patients will receive metformin in combination with androgen deprivation therapy
(ADT) and abiraterone, and the other half will receive ADT and abiraterone only.